Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study

被引：1

作者：

Kuboki, Y. ^{[1
]}

Pietrantonio, F. ^{[2
]}

Salvatore, L. ^{[3
]}

Esaki, T. ^{[4
]}

Modest, D. P. ^{[5
]}

Paez, D. ^{[6
]}

Taieb, J. ^{[7
]}

Ruiz, E. ^{[8
,9
]}

Kim, T. W. ^{[10
]}

Meriggi, F. A. ^{[11
]}

Cunningham, D. ^{[12
,13
]}

Yeh, K-H. ^{[14
]}

Chan, E. ^{[15
]}

Chao, J. ^{[16
]}

Strydom, N. ^{[17
]}

Saportas, Y. ^{[18
]}

Tran, Q. ^{[19
]}

Cremolini, C. ^{[20
]}

Fakih, M. ^{[21
]}

机构：

[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Fdn Policlin Univ Agostino Gemelli IRCC, Dipartimento Oncol, Rome, Italy

[4] Natl Hosp Org, Med Oncol, Kyushu Canc Ctr, Fukuoka, Japan

[5] Charite Univ Med Berlin, Dept Med Hematol Oncol & Tumorimmunol, Berlin, Germany

[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[7] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France

[8] INCAN Inst Nacl Cancerol, GI Oncol Dept, Ciudad De Mexico, Mexico

[9] INCAN Inst Nacl Cancerol, Translat Med Lab, Ciudad De Mexico, Mexico

[10] Univ Ulsan, Asan Med Ctr, Coll Med, Oncol Dept, Seoul, South Korea

[11] Fdn Poliambulanza Ist Osped, Oncol Dept, Brescia, Italy

[12] Inst Canc Res, Med Dept, Sutton, Surrey, England

[13] Royal Marsden Hosp, Sutton, Surrey, England

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[15] Amgen Inc, Global Dev, Thousand Oaks, CA USA

[16] Amgen USA, Oncol Therapeut Area, Seattle, WA USA

[17] Amgen Inc SSF, Clin Pharmacol, San Francisco, CA USA

[18] Amgen Headquarters USA, Global Safety, Thousand Oaks, CA USA

[19] Amgen Headquarters USA, Biostat, Thousand Oaks, CA USA

[20] AOU Pisana Stabilimento Santa Chiara, Polo Oncol, Pisa, Italy

[21] City Hope Comprehens Canc Ctr, Med Oncol Therapeut Res, Duarte, CA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

91MO

引用

页码：S1504 / S1505

页数：2

共 50 条

[21] CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
Fakih, M.
Falchook, G. S.
Hong, D. S.
Yaeger, R. D.
Chan, E.
Mather, O.
Cardona, P.
Dai, T.
Strickler, J.
ANNALS OF ONCOLOGY, 2021, 32 : S551 - S551
[22] Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
Prenen, H.
Fakih, M.
Falchook, G.
Strickler, J.
Hindoyan, A.
Anderson, A.
Ang, A.
Kurata, T.
Price, T.
ANNALS OF ONCOLOGY, 2022, 33 : S373 - S373
[23] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
Strickler, John H.
Rushing, Christel N.
Uronis, Hope Elizabeth
Morse, Michael
Blobe, Gerard C.
Zafar, Yousuf
Hsu, Shiaowen David
Arrowood, Christy
Ley, Sherri Ha
Dropkin, Evan
Niedzwiecki, Donna
Hurwitz, Herbert
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Johnson, M. L.
de langen, A. J.
Waterhouse, D. M.
Mazieres, J.
Dingemans, A-M. C.
Mountzios, G.
Pless, M.
Wolf, J.
Schuler, M.
Lena, H.
Skoulidis, F.
Okamoto, I.
Kim, S-W.
Linardou, H.
Novello, S.
Chen, Y.
Solomon, B.
Obiozor, C.
Wang, Y.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1417 - S1418
[25] Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12Cemutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101
Masuishi, T.
Yamaguchi, K.
Ruffinelli Rodriguez, J. C.
Corral de la Fuente, E.
Kuboki, Y.
Cremolini, C.
Victoria Ruiz, I.
Elez Fernandez, M. E.
Strickler, J. H.
Furqan, M.
Bashir, B.
Nduka, C.
Hippenmeyer, J.
Chan, E.
Xia, C.
Siena, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1432 - S1432
[26] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
Skoulidis, Ferdinandos
De langen, Adrianus
Paz-Ares, Luis G.
Mountzios, Giannis Socrates
Curioni-Fontecedro, Alessandra
Couraud, Sebastien
Janssens, Annelies
Rocco, Danilo
Ohashi, Kadoaki
Vincent, Mark David
Kang, Jin-Hyoung
Schvartsman, Gustavo
Lindsay, Colin R.
O'Byrne, Kenneth John
Dziadziuszko, Rafal
Andersen, Jon A. Lykkegaard
Hindoyan, Antreas
Wilmanski, Tomasz
Wang, Yang
Schuler, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study
Yoshino, T.
Fu, R.
Hawk, N.
Adelberg, D. E.
Norwood, G.
Heinemann, V.
ANNALS OF ONCOLOGY, 2021, 32 : S580 - S580
[28] Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRAS G12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report
Stratton, Natalie
Thompson, Jonathan
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
[29] Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
Barlesi, Fabrice
Felip, Enriqueta
Popat, Sanjay
Solomon, Benjamin J.
Wolf, Juergen
Li, Bob T.
Wu, Yi-Long
Kerr, Keith
Akamatsu, Hiroaki
Camidge, David Ross
Gupta, Ravi G.
Meloni, Alison
Dai, Tian
Borghaei, Hossein
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer
Kavgaci, Gozde
Dizdar, Omer
Yalcin, Suayib
ANTI-CANCER DRUGS, 2024, 35 (05) : 459 - 461

← 1 2 3 4 5 →